Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | PDE1A | P54750 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31104035 | 0.85 | ALDH1A1 (0.38) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL25342107 | 0.83 | ALDH1A1 (0.40) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL31104047 | 0.82 | ALDH1A1 (0.34) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL31104171 | 0.76 | ALDH1A1 (0.40) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL25341195 | 0.75 | RXRA (0.42) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL31103919 | 0.72 | ALDH1A1 (0.40) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL31104287 | 0.71 | ALDH1A1 (0.36) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL15666220 | 0.69 | ALDH1A1 (0.46) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL24177147 | 0.69 | ALDH1A1 (0.39) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL25918978 | 0.68 | ALDH1A1 (0.42) | CYP4F2CYP4A11ALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059161-A1 | COMPOUNDS AND METHODS FOR MODULATING STAT3 | VIVIDION THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059161-A1 | COMPOUNDS AND METHODS FOR MODULATING STAT3 | STAT3, JAK2, STAT1 | CYP4F2 3933/4885CYP4A11 3124/4885ALDH1A1 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.